Novato, California, U.S., October 7, 2026
Ultragenyx Pharmaceutical Inc. has entered into a definitive agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for $210 million, creating a potential source of additional funding for the company’s rare and ultra-rare disease drug development programs. Announced on October 7, 2026, the transaction follows the U.S. Food and Drug Administration (FDA) approval of GENGLYCOS™ (pariglasgene brecaparvovec-opnr), also known as DTX401, a gene therapy designed to address the underlying cause of glycogen storage disease type Ia (GSDIa). Ultragenyx received the voucher following the product’s approval in August 2026. The company expects the proceeds to provide non-dilutive capital to advance its therapeutic pipeline and support its path toward profitability. The sale remains subject to customary closing conditions, including the expiration of the applicable waiting period under U.S. antitrust law. The buyer has not been publicly identified in the announcement.
Ultragenyx Secures $210 Million Voucher Sale Agreement
The agreement gives Ultragenyx the opportunity to monetize a regulatory asset earned through the approval of a rare pediatric disease treatment. Under the announced terms, the buyer will pay $210 million in cash upon closing. The transaction is not yet complete, and the company must satisfy the applicable closing requirements before receiving the proceeds. Ultragenyx said the planned sale is expected to provide financial resources for its work on treatments for serious rare and ultra-rare genetic diseases. The company focuses on conditions with high unmet medical needs and has built a portfolio of approved medicines and investigational candidates. Additional funding may help support clinical development, regulatory activities and the advancement of potential treatments across its pipeline. However, the transaction should not be interpreted as new funding from an equity financing round. A priority review voucher is a transferable regulatory incentive that can be sold to another company. Its sale allows the holder to convert the voucher into cash without issuing additional shares, making the proceeds a form of non-dilutive financing. According to the company’s announcement, Jefferies LLC is serving as exclusive financial advisor, while Gibson, Dunn and Crutcher LLP is providing legal counsel for the transaction.
GENGLYCOS Approval Earns Rare Disease Voucher
Ultragenyx received the voucher after the FDA approved GENGLYCOS, a gene therapy for glycogen storage disease type Ia. GSDIa is a rare inherited metabolic disorder associated with impaired glucose regulation caused by a deficiency in glucose-6-phosphatase activity. The disease can lead to serious complications and requires ongoing management. GENGLYCOS was designed to address the underlying cause of GSDIa rather than solely manage individual symptoms. Its approval represented an important regulatory milestone for the rare disease community and enabled Ultragenyx to qualify for the Rare Pediatric Disease Priority Review Voucher Program. The FDA’s voucher program is intended to encourage the development of medicines and biological products for certain rare pediatric diseases. When an eligible product receives approval, its sponsor may qualify for a voucher that can be redeemed to obtain priority review for a subsequent marketing application covering a different product. The voucher can also be sold or transferred to another eligible holder. Priority review does not guarantee approval of a medicine. Instead, it provides an opportunity for the FDA to review a qualifying application on an expedited timeline. The program creates a potential financial incentive for companies developing treatments for rare diseases, where patient populations are small and research and development can be challenging.
Advertisement
Voucher Proceeds to Support Future Drug Development
Ultragenyx’s management said monetizing the voucher would provide significant financial support for its efforts to develop first-ever therapies for rare and ultra-rare diseases. The company also noted that GENGLYCOS itself benefited from capital generated through a previous voucher sale, illustrating how proceeds from the program can be reinvested in subsequent drug development. A separate agreement with the U.S. National Institutes of Health (NIH) affects the transaction’s financial outcome. Under a patent license agreement dated December 10, 2018, Ultragenyx is required to pay 20% of the gross proceeds from the voucher sale to the NIH after the transaction closes. Consequently, the announced $210 million sale price should not be interpreted as the amount Ultragenyx will retain after this obligation and other applicable costs. The agreement remains subject to customary conditions, including the relevant waiting period under the Hart-Scott-Rodino Antitrust Improvements Act. Until these conditions are satisfied, the sale should be described as an agreement to sell rather than a completed transaction. The announcement highlights the continuing role of regulatory incentive programs in financing rare disease research. For Ultragenyx, the planned voucher sale could help support its pipeline while reinforcing its strategy of developing treatments for serious genetic conditions with limited therapeutic options.
Source: Ultragenyx Pharmaceutical press release
